Source: StemCells, Inc.
Date: December 15, 2011
Summary:
NEWARK, Calif., -- StemCells, Inc. announced today that the first cohort of the Company's Phase I/II clinical trial in chronic spinal cord injury have been successfully transplanted with the Company's proprietary HuCNS-SC® neural stem cells. This landmark clinical trial has a unique design, in which patients with progressively decreasing severity of injury will be treated in three sequential cohorts. The first cohort of patients all have spinal cord injury classified as AIS A, the most severe level identified by the American Spinal Injury Association Impairment Scale (AIS).
Thursday, December 15, 2011
Tuesday, December 13, 2011
HIV Drug Reduces Graft-versus-Host Disease in Stem Cell Transplant Patients, Penn Study Shows
Source: University of Pennsylvania School of Medicine
Date: December 13, 2011
Summary:
(SAN DIEGO) -- An HIV drug that redirects immune cell traffic appears to significantly reduce the dangerous complication graft-versus-host disease (GvHD) in blood cancer patients following allogeneic stem cell transplantation (ASCT), according to new research from the Perelman School of Medicine at the University of Pennsylvania that will be presented today at the 53rd American Society of Hematology Annual Meeting. Standard GvHD treatments suppress the immune system, reducing – but not eliminating – the risk of developing the common problem. In the current trial, treatment with the HIV drug maraviroc dramatically reduced the incidence of GvHD in organs where it is most dangerous -- without compromising the immune system and leaving patients more vulnerable to severe infections.
Date: December 13, 2011
Summary:
(SAN DIEGO) -- An HIV drug that redirects immune cell traffic appears to significantly reduce the dangerous complication graft-versus-host disease (GvHD) in blood cancer patients following allogeneic stem cell transplantation (ASCT), according to new research from the Perelman School of Medicine at the University of Pennsylvania that will be presented today at the 53rd American Society of Hematology Annual Meeting. Standard GvHD treatments suppress the immune system, reducing – but not eliminating – the risk of developing the common problem. In the current trial, treatment with the HIV drug maraviroc dramatically reduced the incidence of GvHD in organs where it is most dangerous -- without compromising the immune system and leaving patients more vulnerable to severe infections.
Monday, December 12, 2011
Study finds iPS cells match embryonic stem cells in modeling human disease
Source: Stanford University School of Medicine
Date: December 12, 2011
Summary:
Stanford University School of Medicine investigators have shown that iPS cells, viewed as a possible alternative to human embryonic stem cells, can mirror the defining defects of a genetic condition — in this instance, Marfan syndrome — as well as embryonic stem cells can. An immediate implication is that iPS cells could be used to examine the molecular aspects of Marfan on a personalized basis. Embryonic stem cells, on the other hand, can’t do this because their genetic contents are those of the donated embryo, not the patient’s.
This proof-of-principle regarding the utility of induced pluripotent stem cells also has more universal significance, as it advances the credibility of an exciting approach that’s been wildly acclaimed by some and viewed through gimlet eyes by others: the prospect of using iPS cells in modeling a broad range of human diseases. These cells, unlike ESCs, are easily obtained from virtually anyone and harbor a genetic background identical to the patient from which they were derived. Moreover, they carry none of the ethical controversy associated with the necessity of destroying embryos.
The study was published online Dec. 12 in Proceedings of the National Academy of Sciences.
Date: December 12, 2011
Summary:
Stanford University School of Medicine investigators have shown that iPS cells, viewed as a possible alternative to human embryonic stem cells, can mirror the defining defects of a genetic condition — in this instance, Marfan syndrome — as well as embryonic stem cells can. An immediate implication is that iPS cells could be used to examine the molecular aspects of Marfan on a personalized basis. Embryonic stem cells, on the other hand, can’t do this because their genetic contents are those of the donated embryo, not the patient’s.
This proof-of-principle regarding the utility of induced pluripotent stem cells also has more universal significance, as it advances the credibility of an exciting approach that’s been wildly acclaimed by some and viewed through gimlet eyes by others: the prospect of using iPS cells in modeling a broad range of human diseases. These cells, unlike ESCs, are easily obtained from virtually anyone and harbor a genetic background identical to the patient from which they were derived. Moreover, they carry none of the ethical controversy associated with the necessity of destroying embryos.
The study was published online Dec. 12 in Proceedings of the National Academy of Sciences.
Thursday, December 08, 2011
Scientists use animal-free reagents to create clinical-grade neurons from skin cells
Source: University of California - Los Angeles
Date: December 8, 2011
Summary:
Using a specially designed facility, UCLA stem cell scientists have taken human skin cells, reprogrammed them into cells with the same unlimited property as embryonic stem cells, and then differentiated them into neurons while completely avoiding the use of animal-based reagents and feeder conditions throughout the process. The study represents the first time scientists have derived induced pluripotent stem (iPS) cells with the potential for clinical use and differentiated them into neurons in animal origin–free conditions using commercially available reagents to facilitate broad application, said Saravanan Karumbayaram, the first author of the study and an associate researcher with the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA. The study was published Dec. 7 in the early online edition of the inaugural issue of the peer-reviewed journal Stem Cells Translational Medicine, a new journal that seeks to bridge stem cell research and clinical trials.
Date: December 8, 2011
Summary:
Using a specially designed facility, UCLA stem cell scientists have taken human skin cells, reprogrammed them into cells with the same unlimited property as embryonic stem cells, and then differentiated them into neurons while completely avoiding the use of animal-based reagents and feeder conditions throughout the process. The study represents the first time scientists have derived induced pluripotent stem (iPS) cells with the potential for clinical use and differentiated them into neurons in animal origin–free conditions using commercially available reagents to facilitate broad application, said Saravanan Karumbayaram, the first author of the study and an associate researcher with the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA. The study was published Dec. 7 in the early online edition of the inaugural issue of the peer-reviewed journal Stem Cells Translational Medicine, a new journal that seeks to bridge stem cell research and clinical trials.
Origins of Blood Stem Cells Determined
Source: University of Pennsylvania School of Medicine
Date: December 8, 2011
Summary:
PHILADELPHIA – A research team at the Perelman School of Medicine at the University of Pennsylvania, has discovered a molecular marker for the immediate precursors of hematopoietic (blood) stem cells (HSCs) in the developing embryo, which provides much-needed insights for making these cells from engineered precursors. Because HSCs, found in the bone marrow of adult mammals, generate all of the blood cell types of the body, unlocking the secrets of their origin may help researchers to better manipulate embryonic stem cells to generate new blood cells for therapy. Speck is also an Investigator with the Abramson Family Cancer Research Institute at Penn. The work was published this week in Cell Stem Cell.
Date: December 8, 2011
Summary:
PHILADELPHIA – A research team at the Perelman School of Medicine at the University of Pennsylvania, has discovered a molecular marker for the immediate precursors of hematopoietic (blood) stem cells (HSCs) in the developing embryo, which provides much-needed insights for making these cells from engineered precursors. Because HSCs, found in the bone marrow of adult mammals, generate all of the blood cell types of the body, unlocking the secrets of their origin may help researchers to better manipulate embryonic stem cells to generate new blood cells for therapy. Speck is also an Investigator with the Abramson Family Cancer Research Institute at Penn. The work was published this week in Cell Stem Cell.
Wednesday, December 07, 2011
Salk researchers develop safe way to repair sickle cell disease genes New gene editing technique would heal patients with their own cells
Source: Salk Institute for Biological Studies
Date: December 7, 2011
Summary:
LA JOLLA, CA—Researchers at the Salk Institute for Biological Studies have developed a way to use patients' own cells to potentially cure sickle cell disease and many other disorders caused by mutations in a gene that helps produce blood hemoglobin. The technique uses cells from a patient's skin to generate induced pluripotent stem cells (iPSCs), which are capable of developing into various types of mature tissues—including blood. The scientists say their method, which repairs the beta-globin gene (HBB), avoids gene therapy techniques that can introduce potentially harmful genes into cells. The new technique, which will soon be tested as a therapy in animals, also appears to be much more efficient than other methods tested to date, the researchers say. The study appears in the December 2011 issue of Cell Research.
Date: December 7, 2011
Summary:
LA JOLLA, CA—Researchers at the Salk Institute for Biological Studies have developed a way to use patients' own cells to potentially cure sickle cell disease and many other disorders caused by mutations in a gene that helps produce blood hemoglobin. The technique uses cells from a patient's skin to generate induced pluripotent stem cells (iPSCs), which are capable of developing into various types of mature tissues—including blood. The scientists say their method, which repairs the beta-globin gene (HBB), avoids gene therapy techniques that can introduce potentially harmful genes into cells. The new technique, which will soon be tested as a therapy in animals, also appears to be much more efficient than other methods tested to date, the researchers say. The study appears in the December 2011 issue of Cell Research.
Research could help people with declining sense of smell
Source: University of California - Berkeley
Date: December 7, 2011
Summary:
University of California, Berkeley, neuroscientists have discovered a genetic trigger that makes the nose renew its smell sensors, providing hope for new therapies for people who have lost their sense of smell due to trauma or old age. The gene tells olfactory stem cells ‑ the adult tissue stem cells in the nose ‑ to mature into the sensory neurons that detect odors and relay that information to the brain. The discovery may also help scientists harness olfactory stem cells and stem cells found in other sensory systems more generally, to recover sensory function following injury or degenerative disease, scientists said. The findings are published in the Dec. 8 issue of the journal Neuron.
Date: December 7, 2011
Summary:
University of California, Berkeley, neuroscientists have discovered a genetic trigger that makes the nose renew its smell sensors, providing hope for new therapies for people who have lost their sense of smell due to trauma or old age. The gene tells olfactory stem cells ‑ the adult tissue stem cells in the nose ‑ to mature into the sensory neurons that detect odors and relay that information to the brain. The discovery may also help scientists harness olfactory stem cells and stem cells found in other sensory systems more generally, to recover sensory function following injury or degenerative disease, scientists said. The findings are published in the Dec. 8 issue of the journal Neuron.
Friday, December 02, 2011
Scalable Amounts of Liver and Pancreas Precursor Cells Created Using New Stem Cell Production Method
Source: Wiley-Blackwell
Date: December 2, 2011
Summary:
Scientists in Canada have overcome a key research hurdle to developing regenerative treatments for diabetes and liver disease with a technique to produce medically useful amounts of endoderm cells from human pluripotent stem cells. The research, published in Biotechnology and Bioengineering, can be transferred to other areas of stem cell research helping scientists to navigate the route to clinical use known as the 'valley of death'.
Date: December 2, 2011
Summary:
Scientists in Canada have overcome a key research hurdle to developing regenerative treatments for diabetes and liver disease with a technique to produce medically useful amounts of endoderm cells from human pluripotent stem cells. The research, published in Biotechnology and Bioengineering, can be transferred to other areas of stem cell research helping scientists to navigate the route to clinical use known as the 'valley of death'.
Thursday, December 01, 2011
researchers identify new method for generating stem cell-like cells from human skin
Source: University of California - Los Angeles
Date: December 1, 2011
Summary:
Researchers from the UCLA School of Dentistry investigating how stem cells can be used to regenerate dental tissue have discovered a way to produce cells with stem cell–like characteristics from the most common type of human skin cell in the epidermis. These skin cells, called keratinocytes, form the outermost layer of skin and can be cultured from discarded skin tissues or biopsy specimens. The findings, published in the Nov. 4 edition of the peer-reviewed Journal of Biological Chemistry, may be beneficial for individuals with limited sources of endogenous stem cells.
Date: December 1, 2011
Summary:
Researchers from the UCLA School of Dentistry investigating how stem cells can be used to regenerate dental tissue have discovered a way to produce cells with stem cell–like characteristics from the most common type of human skin cell in the epidermis. These skin cells, called keratinocytes, form the outermost layer of skin and can be cultured from discarded skin tissues or biopsy specimens. The findings, published in the Nov. 4 edition of the peer-reviewed Journal of Biological Chemistry, may be beneficial for individuals with limited sources of endogenous stem cells.
Subscribe to:
Posts (Atom)